The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
Open accessAbstract
IMPORTANCE: Proton pump inhibitors (PPIs) are among the most commonly used drugs worldwide and have been linked to acute interstitial nephritis. Less is known about the association between PPI use and chronic kidney disease (CKD). OBJECTIVE: To quantify the association between PPI use and incident CKD in a population-based cohort. DESIGN, SETTING, AND PARTICIPANTS: In total, 10,482 participants in the Atherosclerosis Risk in Communities study with an estimated glomerular filtration rate of at least 60 mL/min/1.73 m(2) were followed from a baseline visit between February 1, 1996, and January 30, 1999, to December 31, 2011. The data was analyzed from May 2015 to October 2015. The findings were replicated in an administrative cohort of 248,751 patients with an estimated glomerular filtration rate of at least 60 mL/min/1.73 m(2) from the Geisinger Health System. EXPOSURES: Self-reported PPI use in the Atherosclerosis Risk in Communities study or an outpatient PPI prescription in the Geisinger Health System replication cohort. Histamine2 (H2) receptor antagonist use was considered a negative control and active comparator. MAIN OUTCOMES AND MEASURES: Incident CKD was defined using diagnostic codes at hospital discharge or death in the Atherosclerosis Risk in Communities Study, and by a sustained outpatient estimated glomerular filtration rate of less than 60 mL/min/1.73 m(2) in the Geisinger Health System replication cohort. RESULTS: Among 10,482 participants in the Atherosclerosis Risk in Communities study, the mean (SD) age was 63.0 (5.6) years, and 43.9% were male. Compared with nonusers, PPI users were more often of white race, obese, and taking antihypertensive medication. Proton pump inhibitor use was associated with incident CKD in unadjusted analysis (hazard ratio [HR], 1.45; 95% CI, 1.11-1.90); in analysis adjusted for demographic, socioeconomic, and clinical variables (HR, 1.50; 95% CI, 1.14-1.96); and in analysis with PPI ever use modeled as a time-varying variable (adjusted HR, 1.35; 95% CI, 1.17-1.55). The association persisted when baseline PPI users were compared directly with H2 receptor antagonist users (adjusted HR, 1.39; 95% CI, 1.01-1.91) and with propensity score-matched nonusers (HR, 1.76; 95% CI, 1.13-2.74). In the Geisinger Health System replication cohort, PPI use was associated with CKD in all analyses, including a time-varying new-user design (adjusted HR, 1.24; 95% CI, 1.20-1.28). Twice-daily PPI dosing (adjusted HR, 1.46; 95% CI, 1.28-1.67) was associated with a higher risk than once-daily dosing (adjusted HR, 1.15; 95% CI, 1.09-1.21). CONCLUSIONS AND RELEVANCE: Proton pump inhibitor use is associated with a higher risk of incident CKD. Future research should evaluate whether limiting PPI use reduces the incidence of CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Self-citationChronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Self-citation(1989) · PubMed · Cited by 3,139
Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis
Coca, S. G., Singanamala, S., & Parikh, C. R. (2012) · Kidney International · doi:10.1038/ki.2011.379 · Cited by 2,256
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,191
Clinical consequences of polypharmacy in elderly
Maher, R. L., Hanlon, J., & Hajjar, E. R. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.827660 · Cited by 1,938
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yang, Y.-X., Lewis, J. D., Epstein, S., & Metz, D. C. (2006) · JAMA · doi:10.1001/jama.296.24.2947 · Cited by 1,214
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A., Chertow, G., & Fan, D. (2005) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2004.10.020 · Cited by 773
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Chronic Kidney Disease Diagnosis and Management: A Review
Chen, T. K., Knicely, D. H., & Grams, M. E. (2019) · JAMA · doi:10.1001/jama.2019.14745 · Cited by 1,811
Self-citationBirnkrant, D. J., Bushby, K., Bann, C. M., Apkon, S. D., Blackwell, A., Brumbaugh, D., Case, L. E., Clemens, P. R., Hadjiyannakis, S., Pandya, S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30024-3 · Cited by 1,370
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.-A., Fogo, A. B., Fox, C. S., Gansevoort, R. T., Heerspink, H. J. L., Jardine, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30788-2 · Cited by 919
Self-citationFreedberg, D. E., Kim, L. S., & Yang, Y.-X. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.031 · Cited by 891
The ARIC (Atherosclerosis Risk In Communities) Study
Wright, J. D., Folsom, A. R., Coresh, J., Sharrett, A. R., Couper, D., Wagenknecht, L. E., Mosley, T. H., Ballantyne, C. M., Boerwinkle, E. A., Rosamond, W. D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.035 · Cited by 552
Self-citationMoayyedi, P., Eikelboom, J. W., Bosch, J., Connolly, S. J., Dyal, L., Shestakovska, O., Leong, D., Anand, S. S., Störk, S., Branch, K. R. H., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.056 · Cited by 483
Complications of Proton Pump Inhibitor Therapy
Vaezi, M. F., Yang, Y.-X., & Howden, C. W. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.047 · Cited by 482
Clinical Practice Guideline: Hoarseness (Dysphonia) (Update)
Stachler, R. J., Francis, D. O., Schwartz, S. R., Damask, C. C., Digoy, G. P., Krouse, H. J., McCoy, S. J., Ouellette, D. R., Patel, R. R., Reavis, C. (. W., et al. (2018) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599817751030 · Cited by 368
Drug-Induced Acute Kidney Injury
Perazella, M. A., & Rosner, M. H. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11290821 · Cited by 357
Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD
Xie, Y., Bowe, B., Li, T., Xian, H., Balasubramanian, S., & Al-Aly, Z. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121377 · Cited by 337
Aging human body: changes in bone, muscle and body fat with consequent changes in nutrient intake
JafariNasabian, P., Inglis, J. E., Reilly, W., Kelly, O. J., & Ilich, J. Z. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0603 · Cited by 310
Proton-pump inhibitors: understanding the complications and risks
Malfertheiner, P., Kandulski, A., & Venerito, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.117 · Cited by 297
Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
Kinoshita, Y., Ishimura, N., & Ishihara, S. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18001 · Cited by 271
Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
El Rouby, N., Lima, J. J., & Johnson, J. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461835 · Cited by 263
Reducing major risk factors for chronic kidney disease
Luyckx, V. A., Tuttle, K. R., Garcia-Garcia, G., Gharbi, M. B., Heerspink, H. J. L., Johnson, D. W., Liu, Z.-H., Massy, Z. A., Moe, O., Nelson, R. G., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.003 · Cited by 254
The risks of long-term use of proton pump inhibitors: a critical review
Jaynes, M., & Kumar, A. B. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618809927 · Cited by 254
Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Moledina, D. G., Wilson, F. P., Pober, J. S., Perazella, M. A., Singh, N., Luciano, R. L., Obeid, W., Lin, H., Kuperman, M., Moeckel, G. W., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127456 · Cited by 154
Self-citationPhysiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion
Schubert, M. L. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000392 · Cited by 99
Medication-Induced Interstitial Nephritis in the 21st Century
Nast, C. C. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.11.016 · Cited by 88
Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis
Islam, M. M., Poly, T. N., Walther, B. A., Dubey, N. K., Anggraini Ningrum, D. N., Shabbir, S.-A., & (Jack) Li, Y.-C. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001198 · Cited by 88
Association between proton pump inhibitor use and cognitive function in women
Lochhead, P., Hagan, K., Joshi, A. D., Khalili, H., Nguyen, L. H., Grodstein, F., & Chan, A. T. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.061 · Cited by 83
Koda, R., Watanabe, H., Tsuchida, M., Iino, N., Suzuki, K., Hasegawa, G., Imai, N., & Narita, I. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0848-y · Cited by 77
Clarke, K., Adler, N., Agrawal, D., Bhakta, D., Sata, S. S., Singh, S., Gupta, A., Pahwa, A., Pherson, E., Sun, A., et al. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.09.010 · Cited by 59
de la Coba Ortiz, C., Argüelles Arias, F., Martín de Argila de Prados, C., Júdez Gutiérrez, J., Linares Rodríguez, A., Ortega Alonso, A., Rodríguez de Santiago, E., Rodríguez-Téllez, M., Vera Mendoza, M. I., Aguilera Castro, L., et al. (2016) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2016.4232/2016 · Cited by 54
Common Drug Side Effects and Drug-Drug Interactions in Elderly Adults in Primary Care
Merel, S. E., & Paauw, D. S. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14870 · Cited by 48
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina, D. G., Wilson, F. P., Kukova, L., Obeid, W., Luciano, R., Kuperman, M., Moeckel, G. W., Kashgarian, M., Perazella, M. A., Cantley, L. G., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa169 · Cited by 47
Self-citationMiao, J., & Herrmann, S. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad109 · Cited by 31
“A prospective epidemiologic study using the Atherosclerosis Risk in Communities database in the USA suggested a 31% increase of the risk for PPI-AIN in patients taking twice-daily dosages of PPIs compared to a single daily dosage [34].”
MethodManagement of Drug-Associated Acute Interstitial Nephritis
Barreto, E. F., & Rule, A. D. (2020) · Kidney360 · doi:10.34067/kid.0000042019 · Cited by 16
Metadata
- Authors
- Lazarus, B., Chen, Y., Wilson, F. P., Sang, Y., Chang, A. R., Coresh, J., & Grams, M. E.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2016-02-01
- Volume
- 176
- Issue
- 2
- Pages
- 238
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2227754270
- Cited by
- 729
- References
- 34
- FWCI
- 91.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.